Phase III randomized controlled trials (RCT) in oncology fail to lead to registration of new
therapies more often than RCTs in other medical disciplines. Most RCTs are sponsored by …

Disappointing results from most late-stage clinical trials of cancer therapeutics indicate a
need for improved and more-predictive animal tumor models. This insufficiency of models …

The advent of precision medicine has prompted profound changes in clinical cancer
research, and the rising numbers of new therapeutic agents pose challenges in terms of the …

Historically, phase II oncology trials assessed a treatment's efficacy by examining its tumor
response rate in a single-arm trial. Then, approximately 25 years ago, certain statistical and …

The broad activity of agents blocking the programmed cell death protein 1 and its ligand (the
PD-(L) 1 axis) revolutionized oncology, offering long-term benefit to patients and even …

The addition of chemotherapeutic agents to ionizing radiation has improved survival in many
malignancies. Cure rates may be further improved by adding novel targeted agents to …

The second edition of a clear and accessible guide to the application of statistics in
psychiatric practice. The book expertly describes statistical concepts in clear and simple …

The present paper considers a treatment of cancer with a combination of anti-VEGF
(bevacizumab) and a chemotherapy drug (docetaxel). Since anti-VEGF reduces the …

Introduction This phase 2 randomized study evaluated trebananib (AMG 386), a peptide-Fc
fusion protein that inhibits angiogenesis by neutralizing the interaction of angiopoietin-1 and …

Women continue to be underrepresented in clinical trials, particularly in Phases I and II of
experimental drug studies in spite of legislative guidelines in the USA, Canada, the …